Immunocore Holdings (IMCR) Receivables - Net (2019 - 2026)

Immunocore Holdings (IMCR) has reported Receivables - Net for 8 consecutive years, with $81.1 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net rose 28.53% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (up 28.53% YoY) and the FY2025 annual result came in at $74.0 million, up 17.44% from the prior year.
• Receivables - Net improved to $81.1 million in Q1 2026 per IMCR's latest filing, from $74.0 million in the prior quarter.
• Over the last five years, Receivables - Net for IMCR reached as high as $81.1 million in Q1 2026 and fell as low as $48.3 million in Q3 2022.
• A 5-year average of $63.4 million and a median of $63.0 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net soared 167.25% — and 2023, when it dropped 4.92%.
• Year by year, Receivables - Net stood at $54.8 million in 2022, then retreated by 4.92% to $52.1 million in 2023, then increased by 20.95% to $63.0 million in 2024, then rose by 17.44% to $74.0 million in 2025, then increased by 9.59% to $81.1 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $81.1 million, $74.0 million, and $75.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.